Table 3.
Second line chemotherapy for patients with BRAFV600E mutated colorectal cancer.
| Regimen | Partial response | Stable disease | Progression disease | mPFS (months) |
|---|---|---|---|---|
| VIC (N = 8) | 1 | 5 | 2 | 2.9 |
| Bevacizumab + FOLFOXIRI/FOLFIRI (N = 8) | 1 | 4 | 3 | 9.7 |
| FOLFOXIRI/FOLFIRI (N = 2) | 0 | 0 | 2 | 1.2 |
| Regorafenib/Fruquintinib (N = 3) | 1 | 1 | 1 | 1.8 |